Search research articles
Contact Us
Filters
Showing results (481-490 of 584) with videos related to
Page
of 59
Sort By:
Developmental Cell
|
February 13, 2019
Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo
Frederik J Verweij, Celine Revenu, Guillaume Arras, et al.
British Journal of Cancer
|
November 21, 2007
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
F A L M Eskens, C H Mom, A S T Planting, et al.
The Journal of Antimicrobial Chemotherapy
|
September 11, 2019
Development of an algorithm to discriminate between plasmid- and chromosomal-mediated AmpC β-lactamase production in Escherichia coli by elaborate phenotypic and genotypic characterization
Jordy P M Coolen, Evert P M den Drijver, Jan A J W Kluytmans, et al.
American Journal of Clinical Oncology
|
October 1, 1989
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer
J Verweij, P C de Jong, P H de Mulder, et al.
Iscience
|
August 14, 2023
Exosomal release of the virus-encoded chemokine receptor US28 contributes to chemokine scavenging
Maarten P Bebelman, Irfan M Setiawan, Nick D Bergkamp, et al.
British Journal of Cancer
|
September 9, 2010
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
I R H M Konings, M J A de Jonge, H Burger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
J Verweij, A van Oosterom, J-Y Blay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 13, 2006
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination
R Hoekstra, F Y F L de Vos, F A L M Eskens, et al.
Anti-Cancer Drugs
|
August 7, 2001
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
J H Schellens, P Dombernowsky, J Cassidy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2008
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
E A Eisenhauer, P Therasse, J Bogaerts, et al.
Page
of 59
Search research articles
Search
Showing results (481-490 of 584) with videos related to
Sort By:
Page
of 59
Developmental Cell
|
February 13, 2019
Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo
Frederik J Verweij, Celine Revenu, Guillaume Arras, et al.
British Journal of Cancer
|
November 21, 2007
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
F A L M Eskens, C H Mom, A S T Planting, et al.
The Journal of Antimicrobial Chemotherapy
|
September 11, 2019
Development of an algorithm to discriminate between plasmid- and chromosomal-mediated AmpC β-lactamase production in Escherichia coli by elaborate phenotypic and genotypic characterization
Jordy P M Coolen, Evert P M den Drijver, Jan A J W Kluytmans, et al.
American Journal of Clinical Oncology
|
October 1, 1989
Induction chemotherapy with cisplatin and continuous infusion 5-fluorouracil in locally far-advanced head and neck cancer
J Verweij, P C de Jong, P H de Mulder, et al.
Iscience
|
August 14, 2023
Exosomal release of the virus-encoded chemokine receptor US28 contributes to chemokine scavenging
Maarten P Bebelman, Irfan M Setiawan, Nick D Bergkamp, et al.
British Journal of Cancer
|
September 9, 2010
Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
I R H M Konings, M J A de Jonge, H Burger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study
J Verweij, A van Oosterom, J-Y Blay, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 13, 2006
Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination
R Hoekstra, F Y F L de Vos, F A L M Eskens, et al.
Anti-Cancer Drugs
|
August 7, 2001
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
J H Schellens, P Dombernowsky, J Cassidy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2008
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
E A Eisenhauer, P Therasse, J Bogaerts, et al.
Page
of 59